A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
ConditionSolid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorGuangzhou Virotech Pharmaceutical Co., Ltd.
About this trial
A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
Eligibility criteria
Qualifiers
Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures.
Males and females are aged at 18-75 years (including borderline values) at the time of signing the ICF, male or female.
Subjects are histologically or cytologically confirmed to be intolerable or refractory to the standard systemic treatment.
Subjects have at least one measurable lesion.
Disqualifiers
Subject has received any antitumor therapy within 4 weeks prior to the first dose of IMP.
Subject has previously received oncolytic virus or other gene drug therapy.
Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of IMP.
Subject is known to have an allergic reaction to any of the components of IMP.
Trial design
Treatments tested in this trial
- VRT106
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Guangzhou Virotech Pharmaceutical Co., Ltd.
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Collaborator
Source ClinicalTrials.gov